MET and non-small cell lung carcinoma: In addition to MET exon 14 skipping mutations identified by next-generation sequencing (NGS) of DNA or RNA, MET-expression analyzed by IHC and MET-GCNG/GA status evaluated by fluorescence in situ hybridization (FISH) are considered biomarkers for targeted anti-MET therapy in NSCLC [3,4,5].